Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.Amir A. Jazaeri, Bradley J. Monk, Sajeve Thomas et al.|Journal of Clinical Oncology|2019Cited by 142
492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancersDavid M. O’Malley, Antonio Jimeno, Sylvia Lee et al.|Regular and Young Investigator Award Abstracts|2021Cited by 37
A phase II, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinomaAmir A. Jazaeri, Robert M. Wenham, Robert P. Edwards et al.|Gynecologic Oncology|2018Cited by 6
A phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma.Amir A. Jazaeri, Emese Zsíros, Robert P. Edwards et al.|Journal of Clinical Oncology|2018Cited by 4